Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Therapeutic antibody for cancer-associated cachexia

Award Number: R43CA261184
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/13/2021
PERIOD OF PERFORMANCE END DATE: 06/30/2023

Group Awards By:

View Award Description

Therapeutic antibody for cancer-associated cachexia - Therapeutic antibody for cancer-associated cachexia Abstract Cachexia is a debilitating, wasting disease, characterized by loss of appetite, skeletal muscle, and fat mass. Cancer-associated cachexia constitutes a major unmet medical need, as 80% of patients with advanced cancers exhibit cachexia, and 25% of cancer-related mortalities are derived from cachexia rather than direct tumor burden. Cachexic patients are less tolerant to radiotherapy, chemotherapy, pharmacotherapy, and surgery. For this reason, they receive lower doses, reduced duration of treatment, or are not eligible for treatment, indirectly increasing mortality. There is currently no approved treatment for cachexia. Growth differentiation factor 15 (GDF15) is well documented as a critical mediator of body weight loss, and high GDF15 levels are associated with many cancers. Administration of GDF15 causes weight loss in mice, rats, and primates while blocking GDF15 in models of tumor-associated cachexia rapidly reverses weight loss. We present a high-affinity chimeric monoclonal antibody that neutralizes GDF15 in animal models of tumor-associated cachexia. During this Phase 1 project, we will humanize this lead antibody and demonstrate its equivalence to the parent antibody. Phase 2 studies will advance preclinical testing, including pharmacokinetics and toxicology, in preparation for an IND. The therapeutic antibody to be developed in this project will directly block a major cause of cachexia to enable optimal cancer therapy in cachexic patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	LARIX BIOSCIENCE LLC	1230 BORDEAUX DR	SUNNYVALE	CA	94089	SANTA CLARA	USA	Cancer Treatment Research	000	1	1/11/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	LARIX BIOSCIENCE LLC	1230 BORDEAUX DR	SUNNYVALE	CA	94089	SANTA CLARA	USA	Cancer Treatment Research	000	1	11/1/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $252,282 )
2021	2021	LARIX BIOSCIENCE LLC	1230 BORDEAUX DR	SUNNYVALE	CA	94089	SANTA CLARA	USA	Cancer Treatment Research	000	1	7/13/2021	NEW	$252,282
														Subtotal = $252,282

Grand Total All Awards = $252,282

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Therapeutic antibody for cancer-associated cachexia

Award Number: R43CA261184

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/13/2021

PERIOD OF PERFORMANCE END DATE: 06/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer